JP2020505342A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505342A5 JP2020505342A5 JP2019537357A JP2019537357A JP2020505342A5 JP 2020505342 A5 JP2020505342 A5 JP 2020505342A5 JP 2019537357 A JP2019537357 A JP 2019537357A JP 2019537357 A JP2019537357 A JP 2019537357A JP 2020505342 A5 JP2020505342 A5 JP 2020505342A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- antibody
- cells
- nrn1
- sema7a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022139514A JP2022184862A (ja) | 2017-01-17 | 2022-09-01 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447199P | 2017-01-17 | 2017-01-17 | |
| US62/447,199 | 2017-01-17 | ||
| PCT/US2018/014008 WO2018186924A1 (en) | 2017-01-17 | 2018-01-17 | Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022139514A Division JP2022184862A (ja) | 2017-01-17 | 2022-09-01 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505342A JP2020505342A (ja) | 2020-02-20 |
| JP2020505342A5 true JP2020505342A5 (2) | 2021-03-04 |
Family
ID=63712313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537357A Pending JP2020505342A (ja) | 2017-01-17 | 2018-01-17 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
| JP2022139514A Pending JP2022184862A (ja) | 2017-01-17 | 2022-09-01 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022139514A Pending JP2022184862A (ja) | 2017-01-17 | 2022-09-01 | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11566077B2 (2) |
| EP (1) | EP3570887A4 (2) |
| JP (2) | JP2020505342A (2) |
| CN (1) | CN110740748A (2) |
| CA (1) | CA3049445A1 (2) |
| WO (1) | WO2018186924A1 (2) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| US20220023342A1 (en) * | 2018-11-30 | 2022-01-27 | Institut Gustave Roussy | Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer |
| WO2020146772A1 (en) * | 2019-01-11 | 2020-07-16 | The Johns Hopkins University | Neuritin regulation of t cell anergy and t regulatory cell function |
| CN109913414A (zh) * | 2019-03-21 | 2019-06-21 | 吉林省银丰生物工程技术有限公司 | 肝癌afp特异性人工抗原递呈细胞诱导试剂盒 |
| US20210130438A1 (en) * | 2019-10-28 | 2021-05-06 | The Broad Institute, Inc. | Pan-cancer t cell exhaustion genes |
| JP2023511280A (ja) * | 2020-01-14 | 2023-03-17 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 内因性の脱ユビキチン化酵素をリダイレクトすることによる標的化されたタンパク質の安定化のための組成物及び方法 |
| CA3175322A1 (en) * | 2020-03-17 | 2021-09-23 | Ohio State Innovation Foundation | Designer extracellular vesicles for treating excitotoxicity |
| AU2020447334B2 (en) * | 2020-05-15 | 2025-08-14 | Benethera (Shaoxing) Biotechnology Co.,Ltd. | T cell, preparation method for same, and applications thereof |
| CN111781358A (zh) * | 2020-07-13 | 2020-10-16 | 张瑜 | Xab2蛋白作为卵巢癌预后和/或预测铂类耐药标志物 |
| CN112481375B (zh) * | 2020-08-27 | 2024-02-20 | 江苏大学 | 一种胃癌标志物及其应用 |
| CN114350616A (zh) * | 2022-01-24 | 2022-04-15 | 深圳市先康达生命科学有限公司 | 一种免疫细胞及其制备方法和应用 |
| CN114814231B (zh) * | 2022-03-08 | 2024-08-27 | 上海交通大学医学院附属瑞金医院 | 维甲酸诱导基因i在癌症治疗中的应用 |
| CN114561389A (zh) * | 2022-03-15 | 2022-05-31 | 南通市肿瘤医院 | Vrk1表达抑制剂及其应用 |
| US20230313306A1 (en) * | 2022-03-21 | 2023-10-05 | Feng Xue | Methods of Diagnosis of Alzheimer's Disease by Monitoring STING Signaling Activation |
| CN115631857B (zh) * | 2022-04-01 | 2023-06-23 | 洛兮医疗科技(杭州)有限公司 | 甲状腺癌cd8+t细胞免疫相关基因预后预测模型 |
| CN114720691B (zh) * | 2022-05-10 | 2022-12-09 | 深圳粒影生物科技有限公司 | 一种检测生物标志物的试剂盒及其制备方法和应用 |
| CN115449548A (zh) * | 2022-09-20 | 2022-12-09 | 南京鼓楼医院 | Stac2卵丘细胞在评估卵母细胞受精能力中的应用 |
| CN116904309B (zh) * | 2023-05-26 | 2026-04-03 | 西安天隆科技有限公司 | 能平衡样本管接收部传热差异的模块、方法及pcr装置 |
| CN117192127B (zh) * | 2023-08-18 | 2024-06-14 | 肇庆医学高等专科学校 | 一种hcc治疗靶点的发现方法 |
| CN117590001A (zh) * | 2023-11-22 | 2024-02-23 | 厦门大学 | 外泌体tmem176b在制备诊断肿瘤的药物中的用途 |
| CN119120385B (zh) * | 2024-11-14 | 2025-03-14 | 四川大学华西医院 | 一种具有长效抑瘤效果的嵌合抗原受体t细胞及其制备方法和用途 |
| CN121046325B (zh) * | 2025-11-03 | 2026-03-17 | 杭州克斯珀基因技术有限公司 | 增强肿瘤微环境适应性的cep20敲除型til的制备方法及应用 |
| CN121114292B (zh) * | 2025-11-13 | 2026-01-23 | 合肥谱佳医学检验实验室有限公司 | 体外定量检测人血清中四种神经酰胺化合物的检测试剂盒 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA877772B (en) | 1986-10-23 | 1988-04-20 | Amoco Corporation | Target and background capture methods and apparatus for affinity assays |
| US20070072209A1 (en) | 2005-07-07 | 2007-03-29 | Ashlee Moses | Methods of treatment and diagnosis of Kaposi's sarcoma (KS) and KS related diseases |
| WO2008133641A2 (en) * | 2006-10-11 | 2008-11-06 | Curagen Corporation | Antibodies directed to gpnmb and uses thereof |
| US8637084B2 (en) * | 2009-07-14 | 2014-01-28 | Asahi Kasei Medical Co., Ltd. | Treatment method for epithelial cancerous organism |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| JP2012025694A (ja) * | 2010-07-23 | 2012-02-09 | Asahi Kasei Kuraray Medical Co Ltd | 癌治療剤 |
| PT2614082T (pt) * | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| SG190793A1 (en) | 2010-11-11 | 2013-07-31 | Agency Science Tech & Res | Targeting metabolic enzymes in human cancer |
| CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| WO2014144666A2 (en) * | 2013-03-15 | 2014-09-18 | The University Of Chicago | Methods and compositions related to t-cell activity |
| EP3686219A1 (en) * | 2014-02-04 | 2020-07-29 | Pfizer Inc | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer |
| KR20170068504A (ko) * | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| KR102193635B1 (ko) * | 2015-01-09 | 2020-12-21 | 이투빅스 코포레이션 | 복합 면역요법을 위한 방법 및 조성물 |
| WO2017106656A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| WO2017210523A1 (en) | 2016-06-03 | 2017-12-07 | The Brigham And Women's Hospital | Klrg1 signaling therapy |
-
2018
- 2018-01-17 US US16/476,219 patent/US11566077B2/en active Active
- 2018-01-17 CN CN201880016246.4A patent/CN110740748A/zh active Pending
- 2018-01-17 CA CA3049445A patent/CA3049445A1/en active Pending
- 2018-01-17 WO PCT/US2018/014008 patent/WO2018186924A1/en not_active Ceased
- 2018-01-17 JP JP2019537357A patent/JP2020505342A/ja active Pending
- 2018-01-17 EP EP18780614.6A patent/EP3570887A4/en active Pending
-
2022
- 2022-09-01 JP JP2022139514A patent/JP2022184862A/ja active Pending
-
2023
- 2023-01-06 US US18/151,112 patent/US20230416389A1/en not_active Abandoned
-
2024
- 2024-09-13 US US18/885,340 patent/US20250011452A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505342A5 (2) | ||
| JP7682820B2 (ja) | Ｃａｒの抗腫瘍活性のための毒性管理 | |
| Sharma et al. | Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy | |
| CN113286811B (zh) | 改善过继性细胞疗法的效力和安全性 | |
| CN110475571B (zh) | 细胞免疫疗法前细胞毒性预调理的替代 | |
| Prieto et al. | Immunological landscape and immunotherapy of hepatocellular carcinoma | |
| Aris et al. | Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment | |
| Patel et al. | Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma | |
| Park et al. | Immune therapeutics in the treatment of advanced gastric and esophageal cancer | |
| Wang et al. | What happens to the immune microenvironment after PD-1 inhibitor therapy? | |
| JP7447011B2 (ja) | エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用 | |
| Cabo et al. | Trial watch: immunostimulatory monoclonal antibodies for oncological indications | |
| Hebb et al. | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression | |
| CN108289912A (zh) | 具有提高的免疫力或免疫抑制性细胞因子抗性的免疫细胞及其用途 | |
| JP2017507936A5 (2) | ||
| JP2015508816A5 (2) | ||
| Niedbała et al. | Glioblastoma: pitfalls and opportunities of immunotherapeutic combinations | |
| JP2022523804A (ja) | がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤 | |
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| Zhang et al. | Current advances and challenges in CAR-T therapy for hematological and solid tumors | |
| US20230096897A1 (en) | Lymphocyte Population and Methods for Producing Same | |
| Shah et al. | Multiple myeloma, targeting B-cell maturation antigen with chimeric antigen receptor T-cells | |
| Mandalà et al. | Rational combination of cancer immunotherapy in melanoma | |
| Bose | Immune checkpoint blockers and ovarian cancer | |
| Rossari et al. | Treatment options for advanced hepatocellular carcinoma: the potential of biologics |